Plus Therapeutics Inc (PSTV)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $26.64M
Last updated: Nov 13, 2026 at 4:00 PM ET
Plus Therapeutics Inc (PSTV) Earnings: Report Dates and Results
In the quarter ended Mar 31, 2026, Plus Therapeutics reported EPS of -$1.05, below the -$0.87 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PSTV's report for the quarter ended Sep 30, 2026 is not on the earnings calendar yet.
PSTV Earnings Call
The latest PSTV earnings call transcript on file is labeled 2024Q3.
Read the 2024Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, PSTV beat 20, missed 17 and matched 3. Revenue for the quarter ended Mar 31, 2026 was $1.03M, down 2.8% from $1.06M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | -$1.05 | -$0.87 | -$1.00 - -$0.75 | -20.69% | Miss | N/A | 4 | 0 up, 2 down | May 15, 2026 | $1.03M |
| Dec 31, 2025 | -$0.04 | -$0.04 | -$0.05 - -$0.03 | -12.36% | Miss | N/A | 3 | 1 up, 1 down | Mar 12, 2026 | $1.37M |
| Sep 30, 2025 | -$1.00 | -$0.87 | -$1.00 - -$0.75 | -14.94% | Miss | N/A | 2 | 0 up, 0 down | Oct 30, 2025 | $1.40M |
| Jun 30, 2025 | -$0.16 | -$0.13 | -$0.13 - -$0.13 | -23.08% | Miss | N/A | 1 | 1 up, 0 down | Aug 14, 2025 | $1.39M |
| Mar 31, 2025 | -$14.17 | -$7.33 | -$13.75 - -$2.25 | -93.32% | Miss | N/A | 3 | 2 up, 0 down | May 30, 2025 | $1.06M |
| Dec 31, 2024 | -$0.49 | -$0.50 | -$0.58 - -$0.43 | +1.35% | Beat | N/A | 3 | 1 up, 2 down | Mar 27, 2025 | $1.41M |
| Sep 30, 2024 | -$9.25 | -$14.06 | -$19.50 - -$8.75 | +34.21% | Beat | N/A | 4 | 1 up, 2 down | Nov 14, 2024 | $1.46M |
| Jun 30, 2024 | -$11.25 | -$13.25 | -$17.50 - -$9.25 | +15.09% | Beat | N/A | 3 | 0 up, 0 down | Aug 14, 2024 | $1.28M |
| Mar 31, 2024 | -$18.75 | -$27.25 | -$36.50 - -$18.00 | +31.19% | Beat | N/A | 2 | 0 up, 0 down | May 15, 2024 | $1.68M |
| Dec 31, 2023 | -$0.84 | -$1.07 | -$1.91 - -$0.77 | +21.50% | Beat | N/A | 4 | 0 up, 0 down | Mar 5, 2024 | $1.31M |
| Sep 30, 2023 | -$25.00 | -$29.42 | -$46.50 - -$14.50 | +15.02% | Beat | N/A | 4 | 0 up, 0 down | Oct 31, 2023 | $1.24M |
| Jun 30, 2023 | -$14.75 | -$50.75 | -$62.00 - -$39.25 | +70.94% | Beat | N/A | 4 | 0 up, 0 down | Aug 14, 2023 | $1.85M |
| Mar 31, 2023 | -$52.50 | -$55.00 | N/A | +4.55% | Beat | N/A | 3 | 0 up, 0 down | Apr 20, 2023 | $506000 |
| Dec 31, 2022 | -$0.22 | -$0.12 | -$0.15 - -$0.10 | -83.33% | Miss | N/A | 3 | 0 up, 0 down | Feb 23, 2023 | $151000 |
| Sep 30, 2022 | -$71.25 | -$80.00 | -$82.46 - -$78.71 | +10.94% | Beat | N/A | 2 | 0 up, 0 down | Oct 20, 2022 | $73000 |
| Jun 30, 2022 | -$90.00 | -$71.25 | N/A | -26.32% | Miss | N/A | N/A | 0 up, 0 down | Jul 21, 2022 | N/A |
| Mar 31, 2022 | -$71.25 | -$71.25 | N/A | 0.00% | In line | N/A | 1 | 0 up, 0 down | Apr 21, 2022 | N/A |
| Dec 31, 2021 | -$0.27 | -$0.27 | -$0.27 - -$0.27 | 0.00% | In line | N/A | 1 | N/A | Feb 24, 2022 | N/A |
| Sep 30, 2021 | -$104.77 | -$91.25 | -$101.20 - -$78.71 | -14.82% | Miss | N/A | 3 | 0 up, 0 down | Oct 21, 2021 | N/A |
| Jun 30, 2021 | -$93.75 | -$93.75 | N/A | 0.00% | In line | N/A | 2 | N/A | Jul 22, 2021 | N/A |
| Mar 31, 2021 | -$123.75 | -$146.25 | -$187.41 - -$104.95 | +15.38% | Beat | N/A | 4 | N/A | Apr 22, 2021 | N/A |
| Dec 31, 2020 | -$0.67 | -$0.39 | -$0.55 - -$0.26 | -71.79% | Miss | -391.3% | 4 | N/A | Feb 22, 2021 | N/A |
| Sep 30, 2020 | -$146.25 | -$206.25 | N/A | +29.09% | Beat | N/A | N/A | N/A | Oct 22, 2020 | N/A |
| Jun 30, 2020 | -$0.26 | -$0.75 | -$0.75 - -$0.75 | +65.33% | Beat | N/A | 1 | N/A | Aug 10, 2020 | N/A |
| Mar 31, 2020 | -$266.14 | -$281.25 | N/A | +5.37% | Beat | N/A | 1 | N/A | May 14, 2020 | N/A |
| Dec 31, 2019 | $0.23 | -$0.66 | N/A | +134.85% | Beat | N/A | N/A | N/A | Mar 30, 2020 | $1.19M |
| Sep 30, 2019 | -$11.25 | -$2,193.75 | N/A | +99.49% | Beat | N/A | N/A | N/A | Nov 14, 2019 | N/A |
| Jun 30, 2019 | -$1,920.00 | -$3,750.00 | N/A | +48.80% | Beat | N/A | N/A | N/A | Aug 15, 2019 | N/A |
| Mar 31, 2019 | -$3,375.00 | -$3,656.25 | N/A | +7.69% | Beat | N/A | N/A | N/A | May 14, 2019 | N/A |
| Dec 31, 2018 | -$8.05 | -$14.67 | N/A | +45.13% | Beat | N/A | N/A | N/A | Mar 29, 2019 | N/A |
| Sep 30, 2018 | -$10,312.49 | -$4,500.00 | N/A | -129.17% | Miss | N/A | N/A | N/A | Nov 14, 2018 | N/A |
| Jun 30, 2018 | -$11,062.49 | -$8,925.00 | N/A | -23.95% | Miss | N/A | N/A | N/A | Aug 14, 2018 | N/A |
| Mar 31, 2018 | -$13,124.99 | -$10,000.00 | N/A | -31.25% | Miss | N/A | N/A | N/A | May 10, 2018 | $731000 |
| Dec 31, 2017 | -$50.00 | -$42.50 | N/A | -17.65% | Miss | N/A | N/A | N/A | Mar 8, 2018 | $662000 |
| Sep 30, 2017 | -$26,249.99 | -$29,374.99 | N/A | +10.64% | Beat | N/A | N/A | N/A | Nov 9, 2017 | $467000 |
| Jun 30, 2017 | -$35,624.98 | -$33,749.98 | N/A | -5.56% | Miss | N/A | N/A | N/A | Aug 10, 2017 | $969000 |
| Mar 31, 2017 | -$48,749.98 | -$57,187.47 | N/A | +14.75% | Beat | N/A | N/A | N/A | May 11, 2017 | $591000 |
| Dec 31, 2016 | -$120.00 | -$115.00 | N/A | -4.35% | Miss | N/A | N/A | N/A | Mar 23, 2017 | $1.47M |
| Sep 30, 2016 | -$48,749.98 | -$44,999.98 | N/A | -8.33% | Miss | N/A | N/A | N/A | Nov 9, 2016 | $731000 |
| Jun 30, 2016 | -$80,624.96 | -$73,125.27 | N/A | -10.26% | Miss | N/A | N/A | N/A | Aug 4, 2016 | $1.13M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$15.37, after -$39.74 the year before. It was -$213,869.89 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$15.37 | N/A |
| Dec 31, 2024 | -$39.74 | N/A |
| Dec 31, 2023 | -$93.09 | N/A |
| Dec 31, 2022 | -$232.72 | N/A |
| Dec 31, 2021 | -$322.54 | N/A |
| Dec 31, 2020 | -$413.32 | N/A |
| Dec 31, 2019 | -$5,306.02 | N/A |
| Dec 31, 2018 | -$34,508.02 | N/A |
| Dec 31, 2017 | -$110,674.95 | N/A |
| Dec 31, 2016 | -$213,869.89 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2024Q3 for the period ended Sep 30, 2024, runs about 4,900 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2024Q3 | Sep 30, 2024 | 4,872 | 6 | |
| 2024Q2 | Jun 30, 2024 | 4,722 | 6 |
2024Q3 Earnings Call
Opening remarks
Marc Hedrick President and CEO Thank you, Sheri. Good afternoon, everybody, and thank you once again for taking the time to join us today as we provide an overview of recent business highlights and discuss our third quarter 2024 financial results. Joining me for the call today is Mr. Andrew Sims, our Chief Financial Officer. I'll begin the call by reviewing our recent clinical and corporate progress in the third quarter and then turn the call over to Andrew for a review of our financials, and then we'll both come back for Q&A. I'll begin this afternoon with an overview of our leptomeningeal metastases program in which we are investigating our lead radiotherapeutic Rhenium (186Re) Obisbemeda in ReSPECT-LM trial. As a note, going forward for this call, I'll refer to Rhenium (186Re) Obisbemeda as RNL, which is its research name for the sake of brevity. Part one of our development program, our ongoing ReSPECT-LM Phase 1 single-administration, dose-escalation trial, is perhaps closing in on a maximal dose of 5 in which we administer a very substantial dose of RNL approximately 66 millicuries. The Data Safety and Monitoring Board recommended proceeding to a modified lesser cohort 6 dose of 75 millicuries, and the first patient has been treated. To date, 21 patients have participated, including a subset of three patients who responded well to the initial dose and have received multiple doses under compassionate use. Part two of our integrated development plan is to expand the Phase 1 ReSPECT-LM trial to a multiple dose administration trial. Relatedly, in Q3, we reached agreement with the FDA to proceed under a multiple dose escalation protocol, and we are currently in the site start-up phase for that trial. I'll review that trial design more fully in a moment. In terms of clinical data from the ReSPECT-LM single administration trial, we presented an interim update at the SNO/ASCO conference in August through cohorts 1 through 4. Here are the key highlights from that presentation. Doses of RNL up to 44 millicuries were found to be safe and well tolerated with no dose-limiting toxicities. Pharmacokinetic data demonstrated a very high therapeutic index, specifically about a 50 to 100 target to off-target ratio through cohorts 1 through 3, meaning circulating tumor cells were reduced on average 53% at day 28 post-treatment. The median overall survival for cohorts 1 through 4 was 12 months, which is quite favorable compared to the historically reported consensus of approximately four months with treatment in breast and non-small cell lung cancer. The full presentation from that meeting is available on our website.
Frequently Asked Questions About PSTV
Did PSTV beat earnings estimates last quarter?
No. Plus Therapeutics reported EPS of -$1.05 for the quarter ended Mar 31, 2026, below the -$0.87 estimate by 20.69%.
What EPS do analysts expect from PSTV next quarter?
The consensus EPS estimate for Plus Therapeutics for the quarter ended Sep 30, 2026 is -$0.86 from 3 analysts, with estimates from -$0.92 to -$0.80.
How often does PSTV beat earnings estimates?
Plus Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -14.22%.
PSTV pages: Overview, Earnings, Forecast, Financials, Competitors